Letter to the Editor Regarding “Multiwavelength Photobiomodulation Improves Multiple Aspects of Visual Function in Early-Stage Dry Age-Related Macular Degeneration”

Journal article

We read with interest the recent report by Kkerdnmez and Tedford evaluating multiwavelength photobiomodulation (PBM) in a real-world clinical setting for early-stage nonexudative age-related macular degeneration (AMD) [1].As one of the first non-randomized, single-center assessments of the LumiThera Valeda Light Delivery System (LumiThera, Inc., Poulsbo, WA, USA) outside a controlled trial, this study offers valuable insight into the translational potential of PBM.However, the modest visual acuity gains reported-particularly in the absence of a control or masking-may reflect test-retest variability or learning effects rather than true physiological improvement. A closer analysis of the methodology and results raises important questions regarding the clinical relevance and robustness of the findings. Below, we outline several key concerns.

Authors: Karakosta, C; MacLaren, RE

• Publication status: Published
• Peer review status: Peer reviewed
• Publisher: Springer
• Journal: Ophthalmology and Therapy
• Publication date: 2026-04-18
• Acceptance date: 2026-04-01
• DOI: 10.1007/s40123-026-01382-5
• EISSN: 2193-6528
• ISSN: 2193-8245
• Language: English
• Keywords: Visual acuity; Letter to the editor; Macular degeneration; MEDLINE; Macula Lutea